{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:24:41Z","timestamp":1767007481627},"reference-count":64,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.euroneuro.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,6,22]],"date-time":"2015-06-22T20:27:54Z","timestamp":1435004874000},"page":"1586-1599","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate"],"prefix":"10.1016","volume":"25","author":[{"given":"Ralitza","family":"Gueorguieva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wan-Min","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick G.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Fucito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie S.","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.euroneuro.2015.06.006_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1530-0277.1995.tb01475.x","article-title":"The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior","volume":"19","author":"Anton","year":"1995","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.euroneuro.2015.06.006_bib3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archpsyc.65.2.135","article-title":"An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study","volume":"65","author":"Anton","year":"2008","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.06.006_bib4","first-page":"10","article-title":"Effects of alcoholism typology on response to naltrexone in the COMBINE study","volume":"33","author":"Bogenschutz","year":"2008","journal-title":"ACER"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib6","series-title":"Classification and Regression Trees","first-page":"1984","author":"Breiman","year":"1984"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.06.006_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1037\/a0030886","article-title":"The effects of drinking goal on treatment outcome for alcoholism","volume":"81","author":"Bujarski","year":"2013","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.15288\/jsad.2011.72.135","article-title":"Does family history of alcoholism moderate naltrexone\u2019s effects on alcohol use?","volume":"72","author":"Capone","year":"2011","journal-title":"J. Stud. Alcohol Drugs"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.06.006_bib9","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/art.20821","article-title":"Beer, liquor, and wine consumption and serum uric acid level: the third national health and nutrition examination survey","volume":"51","author":"Choi","year":"2004","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib10","series-title":"The Social Psychology of Health","first-page":"31","article-title":"Perceived stress in a probability sample of the United States","author":"Cohen","year":"1988"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2307\/2136404","article-title":"A global measure of perceived stress","volume":"24","author":"Cohen","year":"1983","journal-title":"J. Health Soc. Beh."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib12","unstructured":"R. Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria 2013. URL \u3008http:\/\/www.R-project.org\/\u3009, 3-900051-07-0."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0899-3289(05)80057-4","article-title":"Stages of change profiles in outpatient alcoholism treatment","volume":"2","author":"DiClemente","year":"1990","journal-title":"J. Subst. Abuse"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.15288\/jsa.1994.55.141","article-title":"The alcohol abstinence self efficacy scale","volume":"55","author":"DiClemente","year":"1994","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/sim.5933","article-title":"Qualitative interaction trees: a tool to identify qualitative treatment-subgroup interactions","volume":"33","author":"Dusseldorp","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1198\/jcgs.2010.06089","article-title":"Combining an additive and tree-based regression model simultaneously: STIMA","volume":"19","author":"Dusseldorp","year":"2010","journal-title":"J. Comput. Graph. Stat."},{"issue":"12","key":"10.1016\/j.euroneuro.2015.06.006_bib17","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/j.1530-0277.2010.01290.x","article-title":"Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials","volume":"34","author":"Falk","year":"2010","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib18","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1002\/sim.4322","article-title":"Subgroup identification from randomized clinical trial data","volume":"30","author":"Foster","year":"2011","journal-title":"Stat. Med."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.06.006_bib19","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.biopsych.2012.03.023","article-title":"Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence","volume":"72","author":"Fucito","year":"2012","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.06.006_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1530-0277.2010.01369.x","article-title":"Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study","volume":"35","author":"Gueorguieva","year":"2011","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.06.006_bib21","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1111\/acer.12541","article-title":"Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT","volume":"38","author":"Gueorguieva","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1037\/0022-006X.58.2.175","article-title":"Commitment to abstinence and acute stress in relapse to alcohol, opiates, and nicotine","volume":"58","author":"Hall","year":"1990","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1037\/0022-006X.58.2.175","article-title":"Commitment to abstinence and acute stress in relapse to alcohol, opiates, and nicotine","volume":"58","author":"Hall","year":"1990","journal-title":"J. Consult. Clin. Psychol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.06.006_bib24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4088\/JCP.13m08940","article-title":"For the Japanese Acamprosate Study Group. Efficacy of acamprosate for the treatment of alcohol dependence long after recovery from withdrawal syndrome: a randomized, double-blind, placebo-controlled study conducted in Japan (Sunrise Study)","volume":"76","author":"Higuchi","year":"2015","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.06.006_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2307\/2955359","article-title":"Self-rated health and mortality: a review of twenty-seven community studies","volume":"38","author":"Idler","year":"1997","journal-title":"J. Health Soc. Behav."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib26","volume":"vol. 1","year":"2004"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib27","article-title":"The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field","volume":"Suppl. 15","author":"Johnson","year":"2005","journal-title":"J. Stud. Alcohol"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.06.006_bib28","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.socscimed.2009.05.013","article-title":"What is self-rated health and why does it predict mortality? Towards a unified conceptual model","volume":"69","author":"Jylha","year":"2009","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib29","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1038\/tp.2014.103","article-title":"Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate","volume":"4","author":"Karpyak","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib30","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.59.10.877","article-title":"Mediators and moderators of treatment effects in randomized clinical trials","volume":"59","author":"Kraemer","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib31","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/10543406.2013.856024","article-title":"Strategies for identifying predictive biomarkers and subgroups with enhanced treatment effect in clinical trials using SIDES","volume":"24","author":"Lipkovich","year":"2014","journal-title":"J. Biopharm. Stat. 2014"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","article-title":"Acamprosate in alcohol dependence: how does it work?","volume":"90","author":"Littleton","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib33","unstructured":"Loh W.Y., He X., Man M. (2014). A Regression Tree Approach to Identifying Subgroups with Differential Treatment Effects. arXiv:1410.1932v1."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib34","series-title":"Project COMBINE: A manual for the Administration for the Important People Instrument","author":"Longabaugh","year":"2002"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.06.006_bib35","doi-asserted-by":"crossref","first-page":"837","DOI":"10.15288\/jsad.2010.71.837","article-title":"Network support as a prognostic indicator of drinking outcomes: the COMBINE study","volume":"71","author":"Longabaugh","year":"2010","journal-title":"J. Stud. Alcohol Drugs"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib36","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1530-0277.2008.00690.x","article-title":"Acamprosate: recent findings and future research directions","volume":"32","author":"Mann","year":"2008","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.06.006_bib37","first-page":"674","article-title":"Searching for responders to acamprosate and naltrexone in alcoholism treatment: rational and design of the PREDICT study","volume":"33","author":"Mann","year":"2009","journal-title":"ACER"},{"issue":"S20","key":"10.1016\/j.euroneuro.2015.06.006_bib38","first-page":"42","article-title":"Treatment of alcohol-dependent outpatients with acamprosate: a clinical review","volume":"62","author":"Mason","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jpsychires.2006.02.002","article-title":"Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo\u2014controlled trail: the role of patient motivation","volume":"40","author":"Mason","year":"2006","journal-title":"J. Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib40","series-title":"Profile of Mood States","author":"McNair","year":"1981"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib41","series-title":"Form 90: A Structured Assessment Interview for Drinking and Related Behaviors. NIAAA Project MATCH Monograph Series","author":"Miller","year":"1996"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib42","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15288\/jsas.1994.s12.112","article-title":"Measurement of drinking behavior using the Form 90 family of instruments","volume":"Suppl. 12","author":"Miller","year":"1994","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib43","article-title":"The Drinking Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse","volume":"Vol. 4","author":"Miller","year":"1995","journal-title":"Test Manual"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11222-005-1311-z","article-title":"Tree-structured subgroup analysis for censored survival data: validation of computationally inexpensive model selection criteria","volume":"15","author":"Negassa","year":"2005","journal-title":"Stat. Comput."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.06.006_bib45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/alcalc\/agp092","article-title":"Alcohol intake and systemic markers of inflammation\u2014shape of the association according to sex and body mass index","volume":"45","author":"Oliveira","year":"2010","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib46","first-page":"239","article-title":"Double-blind randomized multicenter trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"Paille","year":"1995","journal-title":"Alcohol Alcohol."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.06.006_bib47","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/alcalc\/agr160","article-title":"Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy","volume":"47","author":"Perney","year":"2012","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib48","article-title":"Medical management (MM) treatment manual","volume":"vol. 2","author":"Pettinati","year":"2004"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.06.006_bib49","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/archpsyc.64.9.1069","article-title":"Effects of naltrexone on alcohol sensitivity and moderators of medication response","volume":"64","author":"Ray","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib50","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003088-199835050-00001","article-title":"Clinical pharmacokinetics of acamprosate","volume":"35","author":"Saivin","year":"1998","journal-title":"Clin. Pharacokinetics"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib51","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","article-title":"Relapse prevention by acamprosate results from a placebo-controlled study on alcohol dependence","volume":"53","author":"Sass","year":"1996","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.06.006_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1037\/0021-843X.91.3.199","article-title":"Alcohol dependence syndrome: measurement and validation","volume":"91","author":"Skinner","year":"1982","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib53","series-title":"Alcohol consumption measures. In: Allen JP, Columbus M, (Ed.) Assessing Alcohol Problems: A Guide for Clinician and Researchers","first-page":"55","author":"Sobell","year":"1995"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archpsyc.1992.01820080032005","article-title":"The structured Clinical Interview for DSM-III-R (SCID): I. History, rational and description","volume":"49","author":"Spitzer","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.06.006_bib55","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/j.1530-0277.2006.00180.x","article-title":"Effects of acamprosate on sleep during alcohol withdrawal: a double-blind placebo-controlled polysomnographic study in alcohol-dependent patients","volume":"30","author":"Staner","year":"2006","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib56","first-page":"457","article-title":"Interaction trees: exploring the differential effects of an interaction program for breast cancer survivors","volume":"60","author":"Su","year":"2011","journal-title":"Appl. Stat."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib57","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/add.12238","article-title":"Cravings as a mediator and moderator of drinking outcomes in the COMBINE study","volume":"108","author":"Subbaraman","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib58","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-AR)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br. J. Addict."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib59","series-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","first-page":"355","article-title":"The World Health Organization Quality of Life (WHOQOL) assessment instrument","author":"Szabo","year":"1996"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib60","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/j.1530-0277.2003.tb02873.x","article-title":"Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods","volume":"27","author":"The COMBINE Study Research Group","year":"2003","journal-title":"Alcohol.: Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib61","doi-asserted-by":"crossref","first-page":"358","DOI":"10.15288\/jsa.1997.58.358","article-title":"The reliability of Form 90: an instrument for assessing alcohol treatment outcome","volume":"58","author":"Tonnigan","year":"1997","journal-title":"J. Stud. Alcohol"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib62","series-title":"How to Score Version 2 of the SF-12 Health Survey","author":"Ware","year":"2002"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/acer.12605","article-title":"Social network predictors of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study","volume":"39","author":"Worley","year":"2014","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.euroneuro.2015.06.006_bib64","series-title":"Recursive Partitioning and Applications","author":"Zhang","year":"2010"},{"key":"10.1016\/j.euroneuro.2015.06.006_bib65","first-page":"2612","article-title":"Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome","volume":"25","author":"Zhang","year":"2010","journal-title":"Hum. Reprod. 2010"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15001765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X15001765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T15:11:12Z","timestamp":1566918672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X15001765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0924977X15001765"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.006","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}